<DOC>
	<DOCNO>NCT00801255</DOCNO>
	<brief_summary>This 7 cohort study evaluate efficacy safety combination treatment HCV nucleoside polymerase inhibitor ( RO5024048 ) HCV protease inhibitor ( RO5190591/ITMN-191/danoprevir ) patient chronic hepatitis C , genotype 1.Cohorts A , B , C , D G treatment-naive patient , cohort E treatment-experienced exclude null responder , cohort F null responder . Cohorts A B evaluate dose 500mg po bid RO5024048 100mg po q8h RO5190591 , alone combination , 7 14 day . Cohort C evaluate combination treatment either 1000mg po bid RO5024048 100mg q8h RO5190591 500mg po bid RO5024048 200mg q8h RO5190591 14 day . Cohort D evaluate 1000mg po bid RO5024048 200mg q8h RO5190591 14 days.Cohort E evaluate 1000mg RO5024048/600mg RO5190591 po twice daily 14 day , Cohorts F G evaluate 1000mg RO5024048/900mg RO5190591 po twice daily 14 day . Cohorts test sequentially parallel , supported appropriate safety pharmacokinetic data.Following last dose study medication patient option continue treatment Standard care therapy . The anticipated time study treatment &lt; 3 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Combination Treatment With HCV Polymerase Inhibitor ( RO5024048 ) HCV Protease Inhibitor ( RO5190591/Danoprevir ) Genotype 1 Chronic Hepatitis C Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Lactams</mesh_term>
	<criteria>adult patient , 1865 year age ; chronic hepatitis C , genotype 1. decompensated liver disease , impair liver function ; presence history nonhepatitis C chronic liver disease ; HBsAg HIV infection ; history cancer within 5 year , localize situ cancer skin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>